Compass Therapeutics, Inc. (CMPX)
NASDAQ: CMPX · Real-Time Price · USD
0.6961
-0.0666 (-8.73%)
At close: Nov 5, 2026, 4:00 PM EST
0.7309
+0.0348 (5.00%)
After-hours: Nov 5, 2026, 6:37 PM EST
Compass Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
39
Market Cap
125.36M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 850.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 175.14M |
| Cue Biopharma | 37.66M |
| Atrium Therapeutics | 35.84M |
| Innate Pharma | 11.21M |
| Molecular Partners AG | 856.30K |
| Spruce Biosciences | 697.00K |
| Veraxa Biotech AG | 29.54K |
CMPX News
- 3 days ago - Compass Therapeutics to Participate in Upcoming November Investor Events - GlobeNewsWire
- 11 days ago - Compass announces publication of Phase 2/3 COMPANION-002 study - TheFly
- 12 days ago - Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 - GlobeNewsWire
- 22 days ago - Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Compass Therapeutics price target lowered to $8 from $15 at Craig-Hallum - TheFly
- 6 weeks ago - Wedbush downgrades Compass Therapeutics as FDA throws wrench at tovecimig - TheFly
- 6 weeks ago - Compass Therapeutics price target lowered to $4 from $8 at Guggenheim - TheFly
- 6 weeks ago - Compass Therapeutics price target lowered to $12 from $24 at H.C. Wainwright - TheFly